Champions Oncology Inc Stock
Your prediction
Champions Oncology Inc Stock
There is an upward development for Champions Oncology Inc compared to yesterday, with an increase of €0.080 (1.660%).
Pros and Cons of Champions Oncology Inc in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Champions Oncology Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Champions Oncology Inc | 1.660% | -0.407% | 0.823% | -35.948% | -15.517% | 32.432% | -48.421% |
| Heron Therapeutics Inc. | -0.220% | -3.745% | -32.094% | -64.610% | -37.702% | -50.322% | -95.078% |
| Evolus Inc | -6.990% | -4.945% | -5.978% | -68.829% | -36.514% | -55.065% | -67.664% |
| Sangamo Therapeutics Inc. | 18.000% | -12.659% | -29.343% | -56.626% | -25.243% | -83.840% | -97.492% |
News
U.S. Polo Assn. Supports Division I National Intercollegiate Championship, Showcasing the Future of the Sport of Polo
DI Women's and Men's Finals to be Featured in ‘Breakaway: Polo in College' on ESPN
WEST PALM BEACH, FLA. / ACCESS Newswire / April 2, 2026 / U.S. Polo Assn., the official sports brand of
Champions Oncology Names Brian Alexander to Board as Company Advances Data-Driven Oncology Strategy
Appointment underscores Champions' focus on leveraging clinically relevant data to power next-generation oncology R&D
HACKENSACK, NJ / ACCESS Newswire / March 30, 2026 / Champions Oncology,
3 Dividend Champions to Buy and Hold for Decades
There's a saying on Wall Street that "dividends don't lie." Just about every financial metric can be spun by a company's management, but dividends either arrive in the mail or they don't. Companies
